BioSpace News Archive

The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared an increase of 2.5% percent in the company’s quarterly dividend, beginning in the first quarter of 2019.

Illumina, Inc. (NASDAQ: ILMN) today announced the launch of its new high-density genotyping array, the Infinium™ Global Diversity Array

In the news release, Recovery Centers of America Opens Medication-Assisted Treatment Clinic in Trenton, issued 26-Nov-2018 by Recovery Centers of America over PR Newswire, we are advised by the company that the fourth paragraph should be removed from the release. The complete, corrected release follows:

Baxter International Inc. (NYSE:BAX), a global leader in clinical nutrition, is collaborating with the European Foundation for the Care of Newborn Infants (EFCNI) to raise awareness for the new EFCNI standards that address the disparities in newborn care in Europe

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced results from an important study to validate the polygenic component of a forthcoming riskScore™ test for Hispanic women who test negative for a hereditary cancer mutation with the myRisk® Hereditary Cancer test.

SpeeDx Pty. Ltd. announced today it has received CE-IVD marking for its ResistancePlus® GC assay that detects both the sexually transmitted infection (STI) N. gonorrhoeae (GC) and sequences in the gyrA gene of the bacteria associated with susceptibility to ciprofloxacin, a previously used front-line antibiotic treatment.

Approval based on survival benefit of Tecentriq, in combination with Avastin, paclitaxel and carboplatin (chemotherapy), in people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations compared to Avastin plus chemotherapy –

Awarded CRO 2018 Customer Value Leadership Award

New HMO plan provides improved coverage choice at lower premium

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, is presenting updated results from a Phase II clinical trial of Puma’s drug neratinib at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas.